Tags

Type your tag names separated by a space and hit enter

Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe.
Lipids Health Dis. 2013 Feb 04; 12:9.LH

Abstract

BACKGROUND

Statins are frequently administered to reduce low-density lipoprotein cholesterol (LDL-C) and vascular inflammation, because LDL-C and high sensitive C-reactive protein (hs-CRP) are associated with high risk for cardiovascular events. When statins do not reduce LDL-C to desired levels in high-risk patients with coronary artery disease (CAD), ezetimibe can be added or the statin dose can be increased. However, which strategy is more effective for treating patients with CAD has not been established. The present study compares anti-inflammatory effects and lipid profiles in patients with CAD and similar LDL-C levels who were treated by increasing the statin dose or by adding ezetimibe to the original rosuvastatin dose to determine the optimal treatment for such patients.

METHODS

46 patients with high-risk CAD and LDL-C and hs-CRP levels of >70 mg/dL and >1.0 mg/L, respectively, that were not improved by 4 weeks of rosuvastatin (2.5 mg/day) were randomly assigned to receive 10 mg (R10, n = 24) of rosuvastatin or 2.5 mg/day of rosuvastatin combined with 10 mg/day of ezetimibe (R2.5/E10, n = 22) for 12 weeks. The primary endpoint was a change in hs-CRP.

RESULTS

Baseline characteristics did not significantly differ between the groups. At 12 weeks, LDL-C and inflammatory markers (hs-CRP, interleukin-6, tumour necrosis factor-alpha and pentraxin 3) also did not significantly differ between the two groups (LDL-C: R10 vs. R2.5/E10: -19.4 ± 14.2 vs. -22.4 ± 14.3 mg/dL). However, high-density lipoprotein cholesterol (HDL-C) was significantly improved in the R10, compared with R2.5/E10 group (4.6 ± 5.9 vs. 0.0 ± 6.7 mg/dL; p < 0.05).

CONCLUSION

Both enhanced therapies exerted similar anti-inflammatory effects under an equal LDL-C reduction in patients with high-risk CAD despite 2.5 mg/day of rosuvastatin. However, R10 elevated HDL-C more effectively than R2.5/E10.

TRIAL REGISTRATION

UMIN000003746.

Authors+Show Affiliations

Department of Cardiovascular Medicine, Akita University Graduate School of Medicine, Hondo 1-1-1, Akita, 010-8543, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

23374898

Citation

Yamazaki, Daisuke, et al. "Comparison of Anti-inflammatory Effects and High-density Lipoprotein Cholesterol Levels Between Therapy With Quadruple-dose Rosuvastatin and Rosuvastatin Combined With Ezetimibe." Lipids in Health and Disease, vol. 12, 2013, p. 9.
Yamazaki D, Ishida M, Watanabe H, et al. Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe. Lipids Health Dis. 2013;12:9.
Yamazaki, D., Ishida, M., Watanabe, H., Nobori, K., Oguma, Y., Terata, Y., Koyama, T., Iino, K., Kosaka, T., & Ito, H. (2013). Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe. Lipids in Health and Disease, 12, 9. https://doi.org/10.1186/1476-511X-12-9
Yamazaki D, et al. Comparison of Anti-inflammatory Effects and High-density Lipoprotein Cholesterol Levels Between Therapy With Quadruple-dose Rosuvastatin and Rosuvastatin Combined With Ezetimibe. Lipids Health Dis. 2013 Feb 4;12:9. PubMed PMID: 23374898.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe. AU - Yamazaki,Daisuke, AU - Ishida,Masaru, AU - Watanabe,Hiroyuki, AU - Nobori,Kiyoshi, AU - Oguma,Yasunori, AU - Terata,Yutaka, AU - Koyama,Takashi, AU - Iino,Kenji, AU - Kosaka,Toshimitsu, AU - Ito,Hiroshi, Y1 - 2013/02/04/ PY - 2012/12/06/received PY - 2013/01/31/accepted PY - 2013/2/5/entrez PY - 2013/2/5/pubmed PY - 2013/6/29/medline SP - 9 EP - 9 JF - Lipids in health and disease JO - Lipids Health Dis VL - 12 N2 - BACKGROUND: Statins are frequently administered to reduce low-density lipoprotein cholesterol (LDL-C) and vascular inflammation, because LDL-C and high sensitive C-reactive protein (hs-CRP) are associated with high risk for cardiovascular events. When statins do not reduce LDL-C to desired levels in high-risk patients with coronary artery disease (CAD), ezetimibe can be added or the statin dose can be increased. However, which strategy is more effective for treating patients with CAD has not been established. The present study compares anti-inflammatory effects and lipid profiles in patients with CAD and similar LDL-C levels who were treated by increasing the statin dose or by adding ezetimibe to the original rosuvastatin dose to determine the optimal treatment for such patients. METHODS: 46 patients with high-risk CAD and LDL-C and hs-CRP levels of >70 mg/dL and >1.0 mg/L, respectively, that were not improved by 4 weeks of rosuvastatin (2.5 mg/day) were randomly assigned to receive 10 mg (R10, n = 24) of rosuvastatin or 2.5 mg/day of rosuvastatin combined with 10 mg/day of ezetimibe (R2.5/E10, n = 22) for 12 weeks. The primary endpoint was a change in hs-CRP. RESULTS: Baseline characteristics did not significantly differ between the groups. At 12 weeks, LDL-C and inflammatory markers (hs-CRP, interleukin-6, tumour necrosis factor-alpha and pentraxin 3) also did not significantly differ between the two groups (LDL-C: R10 vs. R2.5/E10: -19.4 ± 14.2 vs. -22.4 ± 14.3 mg/dL). However, high-density lipoprotein cholesterol (HDL-C) was significantly improved in the R10, compared with R2.5/E10 group (4.6 ± 5.9 vs. 0.0 ± 6.7 mg/dL; p < 0.05). CONCLUSION: Both enhanced therapies exerted similar anti-inflammatory effects under an equal LDL-C reduction in patients with high-risk CAD despite 2.5 mg/day of rosuvastatin. However, R10 elevated HDL-C more effectively than R2.5/E10. TRIAL REGISTRATION: UMIN000003746. SN - 1476-511X UR - https://www.unboundmedicine.com/medline/citation/23374898/Comparison_of_anti_inflammatory_effects_and_high_density_lipoprotein_cholesterol_levels_between_therapy_with_quadruple_dose_rosuvastatin_and_rosuvastatin_combined_with_ezetimibe_ L2 - https://lipidworld.biomedcentral.com/articles/10.1186/1476-511X-12-9 DB - PRIME DP - Unbound Medicine ER -